Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NODE-303 safety study of self-administered etripamil nasal spray for paroxysmal supraventricular tachycardia
NL-OMON50059Phase 3Withdrawn
- Sponsor
- Milestone Pharmaceuticals
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of etripamil in paroxysmal supraventricular tachycardia (PSVT), sponsored by Milestone Pharmaceuticals. Primary endpoint: Safety of self-administered etripamil nasal spray. Planned start Dec 2019; status: withdrawn.
02
Drugs
etripamil
03
Conditions
paroxysmal supraventricular tachycardia (PSVT)
Beyond the preview
Go deeper on NL-OMON50059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50059.